Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United States

Hum Vaccin Immunother. 2024 Dec 31;20(1):2432745. doi: 10.1080/21645515.2024.2432745. Epub 2024 Dec 9.

Abstract

Respiratory syncytial virus (RSV) is a common cause of acute respiratory illness in individuals of all ages, with adults aged ≥60 years and adults with certain chronic conditions at increased risk of severe RSV-related outcomes. This study evaluates the cost-effectiveness of the adjuvanted RSVPreF3 vaccine versus no vaccine in adults aged ≥60 years in the United States (US). A multi-cohort Markov model was developed with a 5-year time horizon and 1-month cycle length to compare outcomes for no vaccination and one-time adjuvanted RSVPreF3 vaccination (assuming the same vaccination as for influenza vaccines). Clinical parameters (e.g., vaccine efficacy) were based on phase 3 clinical trial data over 3 seasons, with all other inputs obtained from public US sources and scientific literature. Outcomes included total and incremental quality-adjusted life year (QALY) losses and costs, as well as incremental cost-effectiveness ratios (ICERs). Sensitivity analyses were conducted to evaluate the sensitivity of results to inputs. In the base case, the model estimated that vaccinating 52.7 million adults aged ≥60 years with the adjuvanted RSVPreF3 vaccine once would result in 244,424 fewer QALY losses and an incremental societal cost of $4.5 billion over 5 years, with vaccination costs partially offset by reduced disease-related costs. From the societal perspective, adjuvanted RSVPreF3 vaccination resulted in an ICER of $18,430 per QALY gained. Results were relatively robust across sensitivity analyses and indicate that adjuvanted RSVPreF3 vaccination is a cost-effective option for the prevention of RSV in US adults aged ≥ 60 years, reducing the substantial burden within this population.

Keywords: Respiratory syncytial virus; United States; adjuvanted RSVPreF3 vaccine; cost-effectiveness; older adults; vaccination.

MeSH terms

  • Adjuvants, Immunologic* / administration & dosage
  • Adjuvants, Immunologic* / economics
  • Aged
  • Aged, 80 and over
  • Clinical Trials, Phase III as Topic
  • Cost-Benefit Analysis*
  • Female
  • Humans
  • Male
  • Markov Chains
  • Middle Aged
  • Quality-Adjusted Life Years
  • Respiratory Syncytial Virus Infections* / economics
  • Respiratory Syncytial Virus Infections* / epidemiology
  • Respiratory Syncytial Virus Infections* / prevention & control
  • Respiratory Syncytial Virus Vaccines* / administration & dosage
  • Respiratory Syncytial Virus Vaccines* / economics
  • Respiratory Syncytial Virus Vaccines* / immunology
  • Respiratory Syncytial Virus, Human / immunology
  • United States
  • Vaccination / economics
  • Vaccine Efficacy

Substances

  • Respiratory Syncytial Virus Vaccines
  • Adjuvants, Immunologic

Grants and funding

GSK funded this study [GSK study identifier: VEO-000319] and was involved in all stages of study conduct, including analysis of the data. GSK also took in charge all costs associated with the development and publication of this manuscript.